Summit Therapeutics Inc (NASDAQ:SMMT) price on Thursday, May 09,fall -3.63% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $4.78.
A look at the stock’s price movement, the close in the last trading session was $4.96. Turning to its 52-week performance, $5.39 and $1.50 were the 52-week high and 52-week low respectively. Overall, SMMT moved 19.50% over the past month.
Summit Therapeutics Inc’s market cap currently stands at around $3.36 billion.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SMMT is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
SMMT’s current price about 20.42% and 17.30% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 59.09, while 7-day volatility ratio is 11.13% and 9.32% in the 30-day chart. Further, Summit Therapeutics Inc (SMMT) has a beta value of -1.26, and an average true range (ATR) of 0.42.
If we refocus on Summit Therapeutics Inc (NASDAQ:SMMT), historical trading data shows that trading volumes averaged 2.28 million over the past 3 months. The company’s latest data on shares outstanding shows there are 701.66 million shares.
The 88.17% of Summit Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 4.63% of the company’s shares. Current price change has pushed the stock 83.14% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SMMT stock continues to rise going into the next quarter.
